Pacific Biosciences of California, Inc.
PACB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $154,014 | $200,521 | $128,304 | $130,513 |
| % Growth | -23.2% | 56.3% | -1.7% | – |
| Cost of Goods Sold | $116,732 | $147,741 | $79,269 | $71,653 |
| Gross Profit | $37,282 | $52,780 | $49,035 | $58,860 |
| % Margin | 24.2% | 26.3% | 38.2% | 45.1% |
| R&D Expenses | $134,922 | $187,170 | $193,000 | $112,899 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $175,017 | $169,818 | $160,854 | $124,124 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $201,656 | $30,259 | $2,377 | $32,272 |
| Operating Expenses | $511,595 | $387,247 | $356,231 | $269,295 |
| Operating Income | -$474,313 | -$334,467 | -$307,196 | -$210,435 |
| % Margin | -308% | -166.8% | -239.4% | -161.2% |
| Other Income/Exp. Net | $164,778 | $16,308 | -$7,052 | -$64,437 |
| Pre-Tax Income | -$309,535 | -$318,159 | -$314,248 | -$274,872 |
| Tax Expense | $316 | -$11,424 | $0 | -$93,649 |
| Net Income | -$309,851 | -$306,735 | -$314,248 | -$181,223 |
| % Margin | -201.2% | -153% | -244.9% | -138.9% |
| EPS | -1.13 | -1.21 | -1.4 | -0.89 |
| % Growth | 6.6% | 13.6% | -57.3% | – |
| EPS Diluted | -1.07 | -1.21 | -1.4 | -0.89 |
| Weighted Avg Shares Out | 274,488 | 253,629 | 224,550 | 203,621 |
| Weighted Avg Shares Out Dil | 288,366 | 253,629 | 224,550 | 204,136 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $13,412 | $14,343 | $14,690 | $12,530 |
| Depreciation & Amortization | $53,351 | $32,691 | $17,318 | $11,585 |
| EBITDA | -$242,772 | -$271,125 | -$282,240 | -$250,757 |
| % Margin | -157.6% | -135.2% | -220% | -192.1% |